Premium
Neurocognitive effects of switching from methylphenidate‐IR to OROS‐methylphenidate in children with ADHD
Author(s) -
Kim Yeni,
Shin MinSup,
Kim JaeWon,
Yoo HeeJung,
Cho SooChurl,
Kim BoongNyun
Publication year - 2009
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1010
Subject(s) - methylphenidate , neurocognitive , attention deficit hyperactivity disorder , psychology , audiology , clinical psychology , psychiatry , medicine , cognition
Objectives This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH‐IR) to osmotic release oral system methylphenidate (OROS‐MPH). Methods 102 children with attention‐deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH‐IR to OROS‐MPH. Results There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH‐IR to OROS‐MPH. A positive correlation was observed between the improvement in parent/caregiver‐rated IOWA Conners total score (Δ IOWA) and the reduction in commission error ( r = 0.3, p = 0.001) and reduction in reaction time variability ( r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver‐rated IOWA Conners scale total scores were significant predictors of change in commission error ( β = 0.3, p = 0.005, CI = 0.4–2.3, adjusted R 2 = 0.12) and RT variability ( β = 0.3, p = 0.004, CI = 0.5–2.4, adjusted R 2 = 0.09) of visual CPT. Conclusions These data suggest that MPH‐IR may be successfully switched to OROS‐MPH treatment with associated improvements in neurocognitive performance. Large‐scale controlled trials are needed to replicate these findings. Copyright © 2009 John Wiley & Sons, Ltd.